Junshi Biosciences 2026 Interim Results
Analysis based on 8 articles · First reported Aug 26, 2026 · Last updated Aug 27, 2026
The strong revenue growth and return to profitability are likely to boost investor confidence in Junshi Biosciences, potentially supporting its stock price on both the Hong Kong and Shanghai exchanges. The licensing deal with Fosun Pharmaceutical Group and international approvals for toripalimab expand the company's commercial potential and may positively impact its valuation.
Shanghai Junshi Biosciences Co., Ltd announced its 2026 interim financial results and corporate updates. Total revenue for H1 2026 reached approximately RMB1,696 million, a 45% increase year-over-year, driven by strong sales of toripalimab (domestic sales RMB1,299 million, up 36%) and increased out-licensing revenue. The company turned profitable with profit attributable to owners of RMB26 million (RMB153 million excluding share-based payment). R&D expenses were RMB644 million. The company issued technology innovation bonds generating RMB1,000 million net cash inflow, and total cash and financial products reached RMB3,670 million. Pipeline advancements include multiple regulatory approvals for toripalimab in various countries (Oman, Qatar, Singapore, Malaysia, South Africa, Peru, Brazil), NDA acceptance for JS001sc, sNDA approval for TUOYI in combination with disitamab vedotin for urothelial carcinoma, and positive phase 3 results in NSCLC. External collaborations include a licensing agreement with Fosun International — Fosun Wanbang Pharma Group for roconkibart (upfront RMB215 million, milestones up to RMB1,125 million) and a dengue vaccine license from the China — Chinese Academy of Sciences. Chairman Dong Junfeng increased his shareholding by 0.32%.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard